ReviewJournal of clinical gastroenterology
Hepatic Injury in Patients With COVID-19.
Review in Journal of clinical gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.Journal for immunotherapy of cancer · 2021Pooled it
- COVID-19 related biliary injury: A review of recent literature.World journal of gastroenterology · 2023Review
- Post-COVID-19 Cholangiopathy: A Recent Indication for Liver Transplantation.Journal of clinical medicine research · 2023Article
- Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients.World journal of gastroenterology · 2023Review
- Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?Hepatic medicine : evidence and research · 2023Review
- COVID-19 and MAFLD/NAFLD: An updated review.Frontiers in medicine · 2023Review
- SARS-CoV-2 associated liver injury: a six-month follow-up analysis of liver function recovery.Medicine and pharmacy reports · 2022Article
- COVID-19 and the liver: A brief and core review.World journal of hepatology · 2021Review
- Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals.Journal of clinical medicine · 2021Article
- Impact of COVID-19 on liver.World journal of clinical cases · 2021Review
- Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19.Reviews in medical virology · 2021Review
- Liver injury in the era of COVID-19.World journal of gastroenterology · 2021Review
- Elevations in Liver Transaminases in COVID-19: (How) Are They Related?Frontiers in medicine · 2021Article
- Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study.Frontiers in medicine · 2020Article
- Post-COVID-19 Cholangiopathy: A Systematic Review.Journal of clinical and experimental hepatologyReview
- Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) has infected over 2 million people worldwide over the course of just several months. Various studies have highlighted that patients infected with COVID-19 may develop various degrees of liver injury. Here, we discuss the impact of underlying liver disease and manifestations of hepatic injury with COVID-19. We also review mechanisms of hepatic injury.
methodsWe searched the database PubMed for all studies focused on hepatic injury in COVID-19.
resultsWe identified 13 studies that assessed the impact of underlying liver disease in patients infected with COVID-19 (N=3046). Underlying liver disease was one of the most common known comorbid categories in patients infected with COVID-19. Overall, 25% of the patients identified from the 13 studies had hepatic injury. Twenty-one percent and 24% had elevated alanine transaminase and aspartate transaminase values, respectively. Nine percent of the patients had elevated total bilirubin values. Ten of the 13 studies assessed COVID-19 acuity with severity of hepatic injury. In 9 of the 10 studies, clinical outcomes were worse with hepatic injury.
conclusionsLiver injury is highly prevalent in patients that present with COVID-19. Since the liver is one of the most affected organs outside of the respiratory system in COVID-19, more intensive surveillance is warranted for severe cases, particularly among those with pre-existing advanced liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.